NYSE:DGX - Quest Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$101.84 -0.76 (-0.74 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$102.60
Today's Range$101.69 - $102.70
52-Week Range$90.10 - $112.96
Volume427,700 shs
Average Volume999,923 shs
Market Capitalization$13.87 billion
P/E Ratio18.86
Dividend Yield1.96%
Beta0.71

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics logoQuest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DGX
CUSIP74834L10
Phone973-520-2700

Debt

Debt-to-Equity Ratio0.73
Current Ratio1.23
Quick Ratio1.14

Price-To-Earnings

Trailing P/E Ratio18.86
Forward P/E Ratio15.41
P/E Growth2.02

Sales & Book Value

Annual Sales$7.71 billion
Price / Sales1.79
Cash Flow$7.3637 per share
Price / Cash13.83
Book Value$36.35 per share
Price / Book2.80

Profitability

EPS (Most Recent Fiscal Year)$5.40
Net Income$772 million
Net Margins10.19%
Return on Equity15.44%
Return on Assets7.23%

Miscellaneous

Employees45,000
Outstanding Shares135,820,000

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Monday, May 14th. Investors of record on Monday, July 9th will be given a dividend of $0.50 per share on Monday, July 23rd. This represents a $2.00 annualized dividend and a yield of 1.96%. The ex-dividend date is Friday, July 6th. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its Board of Directors has authorized a stock buyback program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 7.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's management believes its shares are undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics (NYSE:DGX) announced its quarterly earnings data on Thursday, April, 19th. The medical research company reported $1.52 EPS for the quarter, meeting the consensus estimate of $1.52. The medical research company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.89 billion. Quest Diagnostics had a return on equity of 15.44% and a net margin of 10.19%. The firm's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period last year, the business earned $1.33 earnings per share. View Quest Diagnostics' Earnings History.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY18 earnings guidance on Thursday, April, 19th. The company provided EPS guidance of $6.50-6.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.60. The company issued revenue guidance of $7.70-7.77 billion, compared to the consensus revenue estimate of $7.72 billion.

What price target have analysts set for DGX?

19 brokers have issued 12-month target prices for Quest Diagnostics' stock. Their predictions range from $86.00 to $123.00. On average, they anticipate Quest Diagnostics' stock price to reach $108.0588 in the next year. View Analyst Ratings for Quest Diagnostics.

Who are some of Quest Diagnostics' key competitors?

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the folowing people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)
  • Dr. Jon R. Cohen, Sr. VP & Group Exec. of Diagnostic Solutions (Age 63)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)

Has Quest Diagnostics been receiving favorable news coverage?

News stories about DGX stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quest Diagnostics earned a coverage optimism score of 0.03 on Accern's scale. They also gave news articles about the medical research company an impact score of 48.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.47%), Fiduciary Management Inc. WI (2.70%), Victory Capital Management Inc. (1.79%), American Century Companies Inc. (1.75%), Allianz Asset Management GmbH (1.71%) and Northern Trust Corp (1.50%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, J E Davis, Jeffrey M Leiden, Jenne K Britell, John B Ziegler, Jon R Cohen, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, LSV Asset Management, Element Capital Management LLC, Royal Bank of Canada, UBS Group AG, New York State Common Retirement Fund, Northern Trust Corp and Federated Investors Inc. PA. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Daniel Stanzione, J E Davis, Jeffrey M Leiden, Jon R Cohen, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Fiduciary Management Inc. WI, BlackRock Inc., American Century Companies Inc., Rockefeller Capital Management L.P., Allianz Asset Management GmbH, Polaris Capital Management LLC and FIL Ltd. View Insider Buying and Selling for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $101.84.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $13.87 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


MarketBeat Community Rating for Quest Diagnostics (DGX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  589 (Vote Underperform)
Total Votes:  899
MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Quest Diagnostics (NYSE:DGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Quest Diagnostics in the last 12 months. Their average twelve-month price target is $108.0588, suggesting that the stock has a possible upside of 6.11%. The high price target for DGX is $123.00 and the low price target for DGX is $86.00. There are currently 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.422.422.352.30
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $108.0588$108.0588$107.00$105.3947
Price Target Upside: 6.11% upside3.27% upside8.00% upside11.18% upside

Quest Diagnostics (NYSE:DGX) Consensus Price Target History

Price Target History for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018Robert W. BairdUpgradeNeutral ➝ Outperform$115.00MediumView Rating Details
3/19/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$113.00 ➝ $115.00LowView Rating Details
3/14/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$103.00LowView Rating Details
3/7/2018ArgusUpgradeHold ➝ Buy$104.14 ➝ $116.00LowView Rating Details
2/13/2018Credit Suisse GroupUpgradeNeutral ➝ Outperform$107.00MediumView Rating Details
2/1/2018Piper Jaffray CompaniesReiterated RatingHold$110.00LowView Rating Details
1/29/2018Goldman SachsInitiated CoverageBuy ➝ Buy$117.00MediumView Rating Details
1/24/2018MizuhoSet Price TargetBuy$113.00LowView Rating Details
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$103.00LowView Rating Details
11/25/2017Jefferies GroupSet Price TargetHold$98.00LowView Rating Details
10/27/2017KeyCorpReiterated RatingHoldN/AView Rating Details
10/20/2017Wells FargoLower Price TargetMarket Perform$88.00 ➝ $86.00N/AView Rating Details
10/20/2017CitigroupLower Price TargetNeutral$110.00 ➝ $98.00N/AView Rating Details
10/17/2017Craig HallumReiterated RatingHold$110.00 ➝ $100.00N/AView Rating Details
10/15/2017SunTrust BanksSet Price TargetHold$105.00N/AView Rating Details
9/25/2017Raymond JamesReiterated RatingOutperform ➝ Market PerformHighView Rating Details
7/25/2017Bank of AmericaUpgradeNeutral ➝ Buy$111.00 ➝ $118.00MediumView Rating Details
7/19/2017BarclaysReiterated RatingHold$110.00LowView Rating Details
7/6/2017UBSBoost Price TargetBuy$115.00 ➝ $123.00N/AView Rating Details
4/23/2017Deutsche BankReiterated RatingBuy$108.00 ➝ $115.00LowView Rating Details
4/12/2017FBR & CoBoost Price TargetOutperform$103.00 ➝ $110.00LowView Rating Details
6/24/2016Jyske BankDowngradeNeutral ➝ SellN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Quest Diagnostics (NYSE:DGX) Earnings History and Estimates Chart

Earnings by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Earnings Estimates

2018 EPS Consensus Estimate: $6.27
2019 EPS Consensus Estimate: $6.73
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.31$1.52$1.40
Q2 20185$1.52$1.77$1.65
Q3 20185$1.53$1.69$1.61
Q4 20185$1.46$1.64$1.60
Q1 20193$1.55$1.58$1.57
Q2 20194$1.58$1.83$1.73
Q3 20193$1.66$1.80$1.74
Q4 20194$1.66$1.73$1.70

Quest Diagnostics (NYSE DGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/23/2018$1.76N/AView Earnings Details
4/19/2018Q1 2018$1.52$1.52$1.8910 billion$1.8840 billionViewN/AView Earnings Details
2/1/2018Q4 2017$1.37$1.40$1.9342 billion$1.9360 billionViewN/AView Earnings Details
10/19/2017Q3 2017$1.35$1.39$1.9203 billion$1.9310 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.42$1.55$1.9444 billion$1.9430 billionViewN/AView Earnings Details
4/20/2017Q1 2017$1.1750$1.33$1.8675 billion$1.8990 billionViewN/AView Earnings Details
1/26/2017Q416$1.27$1.31$1.86 billion$1.86 billionViewListenView Earnings Details
10/20/2016Q316$1.35$1.37$1.53 billion$1.89 billionViewListenView Earnings Details
7/21/2016Q216$1.32$1.34$1.91 billion$1.91 billionViewListenView Earnings Details
4/21/2016Q116$1.12$1.12$1.82 billion$1.86 billionViewListenView Earnings Details
1/28/2016Q415$1.19$1.19$1.85 billion$1.85 billionViewListenView Earnings Details
10/22/2015Q315$1.26$1.28$1.89 billion$1.88 billionViewListenView Earnings Details
7/23/2015Q215$1.23$1.25$1.93 billion$1.93 billionViewListenView Earnings Details
4/23/2015Q115$1.04$1.05$1.85 billion$1.84 billionViewListenView Earnings Details
1/29/2015Q414$1.05$1.08$1.85 billion$1.90 billionViewListenView Earnings Details
10/23/2014Q314$1.08$1.10$1.87 billion$1.90 billionViewListenView Earnings Details
7/24/2014Q214$1.06$1.08$1.88 billion$1.90 billionViewN/AView Earnings Details
4/24/2014Q114$0.89$0.84$1.75 billion$1.75 billionViewListenView Earnings Details
1/30/2014Q413$0.93$0.97$1.74 billion$1.76 billionViewListenView Earnings Details
10/17/2013Q313$1.20$1.02$1.84 billion$1.79 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.10$1.06$1.84 billion$1.8150 billionViewListenView Earnings Details
4/17/2013Q1 2013$1.03$0.89$1.86 billion$1.80 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.02$1.01$1.83 billion$1.77 billionViewListenView Earnings Details
10/17/2012$1.18$1.18ViewN/AView Earnings Details
7/19/2012$1.17$1.17ViewN/AView Earnings Details
4/18/2012$1.01$1.07ViewN/AView Earnings Details
1/24/2012$1.06$1.23ViewN/AView Earnings Details
10/25/2011$1.11$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$1.01$1.00ViewN/AView Earnings Details
1/25/2011$0.91$0.98ViewN/AView Earnings Details
10/20/2010Q3 2010$1.00$1.05ViewN/AView Earnings Details
7/21/2010Q2 2010$1.06$1.07ViewN/AView Earnings Details
4/21/2010Q1 2010$0.98$0.89ViewN/AView Earnings Details
1/25/2010Q4 2009$0.96$0.98ViewN/AView Earnings Details
10/20/2009Q3 2009$0.96$1.02ViewN/AView Earnings Details
7/21/2009Q2 2009$0.94$1.00ViewN/AView Earnings Details
4/21/2009Q1 2009$0.82$0.89ViewN/AView Earnings Details
1/26/2009Q4 2008$0.80$0.87ViewN/AView Earnings Details
10/21/2008Q3 2008$0.81$0.86ViewN/AView Earnings Details
7/22/2008Q2 2008$0.78$0.83ViewN/AView Earnings Details
4/21/2008Q1 2008$0.70$0.72ViewN/AView Earnings Details
2/21/2008Q4 2007$0.78$0.79ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Quest Diagnostics (NYSE:DGX) Dividend Information

Quest Diagnostics pays an annual dividend of $2.00 per share, with a dividend yield of 1.96%. DGX's next quarterly dividend payment will be made on Monday, July 23. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 11.70% each year. Quest Diagnostics pays out 37.04% of its earnings out as a dividend.
Next Dividend:7/23/2018
Annual Dividend:$2.00
Dividend Yield:1.96%
Dividend Growth:11.70% (3 Year Average)
Payout Ratio(s):37.04% (Trailing 12 Months of Earnings)
30.26% (Based on This Year's Estimates)
29.07% (Based on Next Year's Estimates)
27.16% (Based on Cash Flow)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2018quarterly$0.501.94%7/6/20187/9/20187/23/2018
2/1/2018quarterly$0.501.99%4/3/20184/4/20184/18/2018
11/29/2017quarterly$0.451.83%1/8/20181/9/20181/24/2018
8/18/2017quarterly$0.451.72%10/2/201710/3/201710/18/2017
5/16/2017quarterly$0.451.71%7/6/20177/10/20177/24/2017
2/21/2017quarterly$0.451.88%4/3/20174/5/20174/19/2017
11/11/2016quarterly$0.451/6/20171/10/20171/25/2017
8/17/2016quarterly$0.401.88%9/30/201610/4/201610/19/2016
5/18/2016quarterly$0.402.1%7/1/20167/6/20167/20/2016
1/28/2016quarterly$0.402.31%4/4/20164/6/20164/20/2016
12/4/2015quarterly$0.382.22%1/8/20161/12/20161/27/2016
8/18/2015quarterly$0.382.07%10/2/201510/6/201510/21/2015
5/15/2015quarterly$0.382.09%7/6/20157/8/20157/22/2015
1/29/2015quarterly$0.382.13%4/6/20154/8/20154/22/2015
12/4/2014quarterly$0.332.03%1/9/20151/13/20151/28/2015
8/15/2014quarterly$0.332.14%10/3/201410/7/201410/22/2014
5/21/2014quarterly$0.332.3%7/7/20147/9/20147/23/2014
1/30/2014quarterly$0.332.51%4/4/20144/8/20144/23/2014
12/6/2013quarterly$0.301.99%1/3/20141/7/20141/22/2014
8/20/2013quarterly$0.302.03%9/27/201310/1/201310/16/2013
5/21/2013quarterly$0.301.96%6/28/20137/2/20137/17/2013
2/26/2013quarterly$0.302.14%3/28/20134/2/20134/16/2013
(Data available from 1/1/2013 forward)

Insider Trades

Quest Diagnostics (NYSE DGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.79%
Institutional Ownership Percentage: 88.28%
Insider Trading History for Quest Diagnostics (NYSE:DGX)
Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE DGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2018Jon R CohenSVPSell83,669$104.20$8,718,309.80115,426View SEC Filing  
3/5/2018Catherine T DohertySVPSell5,556$101.00$561,156.0078,890View SEC Filing  
3/5/2018J. E DavisEVPSell5,122$101.00$517,322.0048,909View SEC Filing  
2/28/2018Catherine T DohertySVPSell1,820$104.38$189,971.60View SEC Filing  
2/28/2018J. E DavisEVPSell1,798$104.42$187,747.16View SEC Filing  
2/26/2018Catherine T DohertySVPSell397$102.74$40,787.7871,926View SEC Filing  
2/26/2018J. E DavisEVPSell494$102.74$50,753.5641,691View SEC Filing  
2/26/2018Robert A KlugVPSell1,157$103.66$119,934.625,137View SEC Filing  
1/29/2018Stephen H RusckowskiChairmanSell106,840$107.00$11,431,880.00272,956View SEC Filing  
1/24/2018Catherine T DohertySVPSell21,294$104.00$2,214,576.0090,709View SEC Filing  
1/2/2018J. E DavisEVPSell63,880$98.68$6,303,678.40101,423View SEC Filing  
9/12/2017Stephen H RusckowskiChairmanSell59,235$108.16$6,406,857.60220,049View SEC Filing  
9/11/2017Daniel StanzioneDirectorSell40,900$108.07$4,420,063.0041,991View SEC Filing  
9/11/2017Stephen H RusckowskiCEOSell53,933$108.16$5,833,393.28220,049View SEC Filing  
9/5/2017Daniel StanzioneDirectorSell3,803$108.01$410,762.0335,359View SEC Filing  
9/5/2017Stephen H RusckowskiChairmanSell2,525$108.03$272,775.75168,413View SEC Filing  
8/4/2017Jeffrey M LeidenDirectorSell296$106.66$31,571.366,000View SEC Filing  
7/27/2017Jeffrey M LeidenDirectorSell1,304$108.73$141,783.926,296View SEC Filing  
6/19/2017Catherine T DohertySVPSell59,762$107.55$6,427,403.1078,582View SEC Filing  
4/24/2017Jenne K BritellDirectorSell6,111$104.03$635,727.33View SEC Filing  
4/20/2017Michael E PrevoznikSVPSell29,513$100.00$2,951,300.0041,335View SEC Filing  
3/16/2017Michael E PrevoznikSVPSell13,987$100.00$1,398,700.0054,309View SEC Filing  
3/3/2017Catherine T DohertySVPSell7,162$98.28$703,881.3687,809View SEC Filing  
2/27/2017Michael E PrevoznikSVPSell440$97.39$42,851.6041,734View SEC Filing  
1/30/2017Catherine T DohertySVPSell80,000$90.58$7,246,400.00119,321View SEC Filing  
8/19/2016Jenne K BritellDirectorSell4,000$84.76$339,040.00View SEC Filing  
8/10/2016Jenne K BritellDirectorSell4,000$85.20$340,800.00View SEC Filing  
8/3/2016Jeffrey M LeidenDirectorSell6,345$85.62$543,258.907,233View SEC Filing  
7/25/2016John B. ZieglerDirectorSell1,000$84.36$84,360.00View SEC Filing  
5/27/2016Catherine T DohertySVPSell47,334$77.27$3,657,498.18100,402View SEC Filing  
5/12/2016Jenne K BritellDirectorSell8,000$75.68$605,440.006,025View SEC Filing  
5/9/2016Everett CunninghamSVPSell56,312$76.26$4,294,353.1274,949View SEC Filing  
5/6/2016Everett CunninghamSVPSell50,447$76.00$3,833,972.0032,649View SEC Filing  
4/25/2016Catherine T DohertySVPSell29,550$74.45$2,199,997.50106,285View SEC Filing  
3/3/2015Michael E PrevoznikSVPSell3,261$71.16$232,052.76View SEC Filing  
2/11/2015Daniel StanzioneDirectorSell8,000$70.97$567,760.00View SEC Filing  
2/4/2015Gail R WilenskyDirectorSell8,000$72.34$578,720.00View SEC Filing  
2/3/2015John B ZieglerDirectorSell8,000$71.88$575,040.00View SEC Filing  
2/2/2015Thomas F BongiornoVPSell3,000$71.50$214,500.00View SEC Filing  
11/17/2014Jon R CohenSVPSell160,029$63.13$10,102,630.77View SEC Filing  
8/8/2014Catherine T DohertySVPSell25,000$60.12$1,503,000.00View SEC Filing  
8/4/2014Michael E PrevoznikSVPSell14,377$61.01$877,140.77View SEC Filing  
7/30/2014Jenne K BritellDirectorSell8,000$62.37$498,960.00View SEC Filing  
7/30/2014Michael E PrevoznikSVPSell16,384$62.51$1,024,163.84View SEC Filing  
7/29/2014John C Md BaldwinDirectorSell8,000$62.31$498,480.00View SEC Filing  
7/28/2014Thomas F BongiornoVPSell4,000$61.72$246,880.00View SEC Filing  
7/25/2014John B ZieglerDirectorSell8,000$61.90$495,200.00View SEC Filing  
5/22/2014John ZieglerDirectorSell2,973$57.65$171,393.4516,825View SEC Filing  
5/7/2014Gary PfeifferDirectorSell10,000$55.95$559,500.0013,927View SEC Filing  
5/5/2014Mark GuinanCFOBuy4,000$55.51$222,040.0044,222View SEC Filing  
2/27/2014Jenne BritellDirectorSell10,000$52.74$527,400.0012,227View SEC Filing  
2/19/2014Michael PrevoznikSVPSell2,860$52.26$149,463.6045,762View SEC Filing  
2/18/2014Gail WilenskyDirectorSell30,000$52.93$1,587,900.0015,927View SEC Filing  
2/6/2014Timothy MainDirectorBuy5,000$50.71$253,550.005,658View SEC Filing  
11/5/2013Thomas F BongiornoVPSell16,667$62.49$1,041,520.83View SEC Filing  
10/29/2013Thomas F BongiornoVPSell6,000$59.00$354,000.00View SEC Filing  
10/25/2013Gary M PfeifferDirectorSell2,000$58.10$116,200.00View SEC Filing  
9/17/2013Catherine DohertySVPSell43,334$62.00$2,686,708.0072,295View SEC Filing  
8/14/2013Catherine DohertySVPSell33,000$59.85$1,975,050.0072,290View SEC Filing  
8/12/2013John ZieglerDirectorSell1,953$59.45$116,105.8515,876View SEC Filing  
8/8/2013Thomas BongiornoVPSell10,864$59.33$644,561.1214,086View SEC Filing  
7/23/2013Jenne K BritellDirectorSell4,200$58.99$247,758.00View SEC Filing  
6/18/2013Michael E PrevoznikSVPSell126,667$62.64$7,934,420.88View SEC Filing  
5/22/2013John B ZieglerDirectorSell31,362$62.00$1,944,444.00View SEC Filing  
5/14/2013John C Md BaldwinDirectorSell1,214$59.41$72,123.74View SEC Filing  
4/11/2013John B ZieglerDirectorSell1,470$58.35$85,774.50View SEC Filing  
1/17/2013Gary M PfeifferDirectorSell10,000$60.00$600,000.00View SEC Filing  
10/3/2012Robert HagemannCFOSell46,667$64.00$2,986,688.00View SEC Filing  
8/7/2012Stephen H RusckowskiCEOBuy5,000$59.34$296,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Quest Diagnostics (NYSE DGX) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Quest Diagnostics (DGX) Will Announce Quarterly Sales of $1.94 BillionZacks: Analysts Expect Quest Diagnostics (DGX) Will Announce Quarterly Sales of $1.94 Billion
www.americanbankingnews.com - May 19 at 2:12 AM
 Analysts Anticipate Quest Diagnostics (DGX) Will Announce Earnings of $1.72 Per Share Analysts Anticipate Quest Diagnostics (DGX) Will Announce Earnings of $1.72 Per Share
www.americanbankingnews.com - May 17 at 9:18 PM
Quest Diagnostics adds Helen Torley to Board of DirectorsQuest Diagnostics adds Helen Torley to Board of Directors
finance.yahoo.com - May 17 at 5:58 PM
Critical Survey: Quest Diagnostics (DGX) versus Veracyte (VCYT)Critical Survey: Quest Diagnostics (DGX) versus Veracyte (VCYT)
www.americanbankingnews.com - May 16 at 1:09 AM
Quest Diagnostics declares $0.50 dividendQuest Diagnostics declares $0.50 dividend
seekingalpha.com - May 15 at 1:48 AM
Quest Diagnostics Plans Quarterly Dividend of $0.50 (DGX)Quest Diagnostics Plans Quarterly Dividend of $0.50 (DGX)
www.americanbankingnews.com - May 14 at 7:04 PM
Invitae (NVTA) vs. Quest Diagnostics (DGX) Financial SurveyInvitae (NVTA) vs. Quest Diagnostics (DGX) Financial Survey
www.americanbankingnews.com - May 13 at 1:33 PM
Quest Diagnostics (DGX) Receives Average Rating of "Hold" from BrokeragesQuest Diagnostics (DGX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 10 at 2:11 PM
Workforce Drug Positivity at Highest Rate in a...Workforce Drug Positivity at Highest Rate in a...
www.prnewswire.com - May 8 at 6:00 PM
Workforce Drug Positivity at Highest Rate in a Decade, Finds Analysis of More Than 10 Million Drug Test ResultsWorkforce Drug Positivity at Highest Rate in a Decade, Finds Analysis of More Than 10 Million Drug Test Results
finance.yahoo.com - May 8 at 6:00 PM
[$$] More U.S. Workers Test Positive for Illicit Drugs[$$] More U.S. Workers Test Positive for Illicit Drugs
finance.yahoo.com - May 8 at 8:00 AM
Forbes Names Quest Diagnostics One of Americas Best Large EmployersForbes Names Quest Diagnostics One of America's Best Large Employers
finance.yahoo.com - May 7 at 5:52 PM
Quest Diagnostics To Speak At The Deutsche Bank 43rd Annual Health Care ConferenceQuest Diagnostics To Speak At The Deutsche Bank 43rd Annual Health Care Conference
www.prnewswire.com - May 4 at 5:48 PM
William Blair Brokers Reduce Earnings Estimates for Quest Diagnostics (DGX)William Blair Brokers Reduce Earnings Estimates for Quest Diagnostics (DGX)
www.americanbankingnews.com - May 2 at 9:06 AM
UPDATE: Baird Upgrades Quest Diagnostics (DGX) to OutperformUPDATE: Baird Upgrades Quest Diagnostics (DGX) to Outperform
www.streetinsider.com - May 2 at 8:05 AM
This Mornings Technical Outlook on Medical Research Stocks -- HTG Molecular Diagnostics, PRA Health Sciences, Quest Diagnostics, and TrovaGeneThis Morning's Technical Outlook on Medical Research Stocks -- HTG Molecular Diagnostics, PRA Health Sciences, Quest Diagnostics, and TrovaGene
www.bizjournals.com - May 2 at 8:05 AM
Lab Stocks: Baird Favors Laboratory Corp., Says Quest Diagnostics Is The Simple ChoiceLab Stocks: Baird Favors Laboratory Corp., Says Quest Diagnostics Is The Simple Choice
finance.yahoo.com - May 2 at 8:05 AM
 Analysts Expect Quest Diagnostics (DGX) Will Post Quarterly Sales of $1.94 Billion Analysts Expect Quest Diagnostics (DGX) Will Post Quarterly Sales of $1.94 Billion
www.americanbankingnews.com - May 2 at 4:24 AM
Quest Diagnostics (DGX) Upgraded by Robert W. Baird to OutperformQuest Diagnostics (DGX) Upgraded by Robert W. Baird to Outperform
www.americanbankingnews.com - May 1 at 9:08 AM
Here's How 3 Big Companies Are Betting on a Blockchain FutureHere's How 3 Big Companies Are Betting on a Blockchain Future
finance.yahoo.com - May 1 at 8:04 AM
William Blair Equities Analysts Boost Earnings Estimates for Quest Diagnostics (DGX)William Blair Equities Analysts Boost Earnings Estimates for Quest Diagnostics (DGX)
www.americanbankingnews.com - May 1 at 7:04 AM
Quest Diagnostics (DGX) Expected to Announce Earnings of $1.72 Per ShareQuest Diagnostics (DGX) Expected to Announce Earnings of $1.72 Per Share
www.americanbankingnews.com - April 30 at 7:31 AM
Edited Transcript of DGX earnings conference call or presentation 19-Apr-18 12:30pm GMTEdited Transcript of DGX earnings conference call or presentation 19-Apr-18 12:30pm GMT
finance.yahoo.com - April 26 at 8:01 AM
Quest Diagnostics (DGX) Lowered to "Hold" at Zacks Investment ResearchQuest Diagnostics (DGX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 12:14 PM
Comparing Quest Diagnostics (DGX) & Biocept (BIOC)Comparing Quest Diagnostics (DGX) & Biocept (BIOC)
www.americanbankingnews.com - April 23 at 11:24 AM
Elekta (EKTAY) vs. Quest Diagnostics (DGX) Head to Head ReviewElekta (EKTAY) vs. Quest Diagnostics (DGX) Head to Head Review
www.americanbankingnews.com - April 23 at 9:30 AM
Piper Jaffray Research Analysts Lift Earnings Estimates for Quest Diagnostics (DGX)Piper Jaffray Research Analysts Lift Earnings Estimates for Quest Diagnostics (DGX)
www.americanbankingnews.com - April 23 at 2:46 AM
Quest Diagnostics to Post Q4 2018 Earnings of $1.63 Per Share, SunTrust Banks Forecasts (DGX)Quest Diagnostics to Post Q4 2018 Earnings of $1.63 Per Share, SunTrust Banks Forecasts (DGX)
www.americanbankingnews.com - April 23 at 2:30 AM
BRIEF-Quest Diagnostics Qtrly Revenue Of $1.88 Bln, Up 3.7 PctBRIEF-Quest Diagnostics Qtrly Revenue Of $1.88 Bln, Up 3.7 Pct
www.reuters.com - April 21 at 5:29 PM
Quest Diagnostics to Post Q1 2018 Earnings of $1.52 Per Share, Piper Jaffray Forecasts (DGX)Quest Diagnostics to Post Q1 2018 Earnings of $1.52 Per Share, Piper Jaffray Forecasts (DGX)
www.americanbankingnews.com - April 20 at 7:26 AM
Quest Diagnostics (DGX) Price Target Increased to $123.00 by Analysts at UBSQuest Diagnostics (DGX) Price Target Increased to $123.00 by Analysts at UBS
www.americanbankingnews.com - April 19 at 8:00 PM
Quest Diagnostics (DGX) CEO Stephen Rusckowski on Q1 2018 Results - Earnings Call TranscriptQuest Diagnostics' (DGX) CEO Stephen Rusckowski on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 19 at 5:56 PM
Is It Time To Buy Quest Diagnostics Incorporated (NYSE:DGX) Based Off Its PE Ratio?Is It Time To Buy Quest Diagnostics Incorporated (NYSE:DGX) Based Off Its PE Ratio?
finance.yahoo.com - April 19 at 5:56 PM
Quest Diagnostics (DGX) Announces Quarterly  Earnings ResultsQuest Diagnostics (DGX) Announces Quarterly Earnings Results
www.americanbankingnews.com - April 19 at 9:50 AM
Quest Diagnostics (DGX) Issues FY18 Earnings GuidanceQuest Diagnostics (DGX) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 19 at 9:10 AM
Quest Diagnostics Q1 adjusted earnings of $1.52 per shareQuest Diagnostics Q1 adjusted earnings of $1.52 per share
www.nasdaq.com - April 19 at 8:05 AM
Quest Diagnostics (DGX) Tops Q1 Earnings, Misses RevenuesQuest Diagnostics (DGX) Tops Q1 Earnings, Misses Revenues
www.zacks.com - April 19 at 8:05 AM
Is a Surprise Coming for Quest Diagnostics (DGX) This Earnings Season?Is a Surprise Coming for Quest Diagnostics (DGX) This Earnings Season?
finance.yahoo.com - April 19 at 8:05 AM
Quest Diagnostics profit climbs 8.2%Quest Diagnostics profit climbs 8.2%
www.marketwatch.com - April 19 at 8:05 AM
Quest Diagnostics Reports First Quarter 2018 Financial ResultsQuest Diagnostics Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 19 at 8:05 AM
Quest Diagnostics: 1Q Earnings SnapshotQuest Diagnostics: 1Q Earnings Snapshot
finance.yahoo.com - April 19 at 8:05 AM
Quest Diagnostics beats by $0.02, misses on revenueQuest Diagnostics beats by $0.02, misses on revenue
seekingalpha.com - April 19 at 6:52 AM
Static UnitedHealth Group Inc Stock Doesnt Offer Much UpsideStatic UnitedHealth Group Inc Stock Doesn't Offer Much Upside
investorplace.com - April 18 at 5:54 PM
BidaskClub Lowers Quest Diagnostics (DGX) to BuyBidaskClub Lowers Quest Diagnostics (DGX) to Buy
www.americanbankingnews.com - April 18 at 12:16 PM
Quest Diagnostics (DGX) Raised to Buy at Zacks Investment ResearchQuest Diagnostics (DGX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:12 AM
Barclays Reiterates Hold Rating for Quest Diagnostics (DGX)Barclays Reiterates Hold Rating for Quest Diagnostics (DGX)
www.americanbankingnews.com - April 17 at 4:47 PM
Quest Diagnostics (DGX) Cut to Hold at BidaskClubQuest Diagnostics (DGX) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 7:00 PM
Bank of America Upgrades Quest Diagnostics (DGX) to "Buy"Bank of America Upgrades Quest Diagnostics (DGX) to "Buy"
www.americanbankingnews.com - April 16 at 12:37 PM
Quest Diagnostics (DGX) Upgraded to "Buy" by Zacks Investment ResearchQuest Diagnostics (DGX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 15 at 7:21 PM
Quest Diagnostics (DGX) Receives Consensus Rating of "Hold" from AnalystsQuest Diagnostics (DGX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 2:01 PM

SEC Filings

Quest Diagnostics (NYSE:DGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Quest Diagnostics (NYSE:DGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Quest Diagnostics (NYSE DGX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.